- Home
- Publications
- Publication Search
- Publication Details
Title
Small Molecule NF-κB Pathway Inhibitors in Clinic
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 14, Pages 5164
Publisher
MDPI AG
Online
2020-07-22
DOI
10.3390/ijms21145164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
- (2020) Naveen Pemmaraju et al. BLOOD
- Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
- (2020) Yuqin Song et al. BLOOD
- A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma
- (2020) Monica M. Mita et al. CLINICAL CANCER RESEARCH
- Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
- (2020) Xiumei Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
- (2020) Maria Gavriatopoulou et al. LEUKEMIA
- Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
- (2020) David J. Sherman et al. MOLECULES
- Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer
- (2020) Mehdi Sharifi-Rad et al. MOLECULES
- Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
- (2020) Sisi Xie et al. Frontiers in Pharmacology
- The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
- (2020) Jessica Michie et al. Cells
- Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants
- (2020) Ian M. Catlett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Practical Review of Proteasome Pharmacology
- (2019) Tiffany A. Thibaudeau et al. PHARMACOLOGICAL REVIEWS
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
- (2019) C. Owen et al. Current Oncology
- A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
- (2019) Drew W. Rasco et al. JOURNAL OF CLINICAL ONCOLOGY
- EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
- (2019) Patrick Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Small Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL) - Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization
- (2019) Min Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Neddylation: a novel modulator of the tumor microenvironment
- (2019) Lisha Zhou et al. Molecular Cancer
- Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents
- (2019) Elmira Ekincia et al. Recent Patents on Anti-Cancer Drug Discovery
- Ubiquitin Ligases cIAP1 and cIAP2 Limit Cell Death to Prevent Inflammation
- (2019) Jieqiong Zhang et al. Cell Reports
- A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
- (2019) Christian Kaltschmidt et al. Cancers
- Proinflammatory NFkB signalling promotes mitochondrial dysfunction in skeletal muscle in response to cellular fuel overloading
- (2019) Raid B. Nisr et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
- (2019) Alia Ghoneum et al. Cancers
- Current Trends in the Analysis of Post-translational Modifications
- (2019) Dávid Virág et al. CHROMATOGRAPHIA
- Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
- (2019) Eric P. Hoffman et al. NEUROLOGY
- Recent Advance of Akt Inhibitors in Clinical Trials
- (2019) Kaiwen Guo et al. ChemistrySelect
- Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information
- (2019) Anas Younes et al. BLOOD
- A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- (2019) Nadine Kutsch et al. BLOOD
- Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- (2019) Motoo Nagane et al. BLOOD
- Cellular quality control by the ubiquitin-proteasome system and autophagy
- (2019) Christian Pohl et al. SCIENCE
- Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
- (2019) Simon A. Rule et al. LEUKEMIA
- Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy
- (2019) Ekta Khattar et al. Nature Communications
- Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer
- (2019) James O’Connell et al. Nature Communications
- NF-κB in the crosshairs: Rethinking an old riddle
- (2018) Jason Bennett et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Noncoding RNAs: Master Regulators of Inflammatory Signaling
- (2018) Chen Li Chew et al. TRENDS IN MOLECULAR MEDICINE
- Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway
- (2018) Guangrui Li et al. Scientific Reports
- The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms
- (2018) Petra Zimmermann et al. Frontiers in Immunology
- Carfilzomib-Associated Cardiovascular Adverse Events
- (2018) Adam J. Waxman et al. JAMA Oncology
- Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
- (2018) Abbey R. Sadowski et al. BMC Veterinary Research
- Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
- (2018) Neeraj Gupta et al. CLINICAL PHARMACOKINETICS
- Cell-Permeable Bicyclic Peptidyl Inhibitors against NEMO-IκB Kinase Interaction Directly from a Combinatorial Library
- (2018) Curran A. Rhodes et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells
- (2018) Masashi Fukuoka et al. PLoS One
- Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1
- (2018) Xueyong Xu et al. Nature Communications
- Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
- (2018) Jack W. Singer et al. Oncotarget
- Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors
- (2018) Jack Prescott et al. Cells
- Recent clinical trends in Toll-like receptor targeting therapeutics
- (2018) Muhammad Ayaz Anwar et al. MEDICINAL RESEARCH REVIEWS
- Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport
- (2018) Friederike Kosyna et al. Cells
- Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
- (2017) Sun Ku Lee et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The transcriptional program, functional heterogeneity, and clinical targeting of mast cells
- (2017) Gökhan Cildir et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structural characterization of interactions between transactivation domain 1 of the p65 subunit of NF-κB and transcription regulatory factors
- (2017) Lauriane Lecoq et al. NUCLEIC ACIDS RESEARCH
- IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof-of-concept study
- (2017) K. Grothe et al. OSTEOARTHRITIS AND CARTILAGE
- Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-κB
- (2017) Leen Catrysse et al. TRENDS IN CELL BIOLOGY
- New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders
- (2017) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
- (2017) C A van der Weyden et al. Blood Cancer Journal
- Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
- (2017) R T Swords et al. Blood Cancer Journal
- CRM1 Inhibitors for Antiviral Therapy
- (2017) Cynthia Mathew et al. Frontiers in Microbiology
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
- (2016) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- The emerging complexity of ubiquitin architecture
- (2016) Fumiaki Ohtake et al. JOURNAL OF BIOCHEMISTRY
- The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling
- (2016) Fumiaki Ohtake et al. MOLECULAR CELL
- Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies
- (2016) Maroof Hasan et al. PHARMACOLOGICAL RESEARCH
- Activation of mutantTERTpromoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas
- (2016) Yinghui Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Noncanonical NF-κB Signaling in Health and Disease
- (2016) Gökhan Cildir et al. TRENDS IN MOLECULAR MEDICINE
- New investigational drugs with single-agent activity in multiple myeloma
- (2016) A M Rajan et al. Blood Cancer Journal
- Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
- (2016) Jing-di Liu et al. Scientific Reports
- Non-antibiotic 12-membered macrolides: design, synthesis and biological evaluation in a cigarette-smoking model
- (2015) Akihiro Sugawara et al. JOURNAL OF ANTIBIOTICS
- The PI3K/AKT Pathway and Renal Cell Carcinoma
- (2015) Huifang Guo et al. Journal of Genetics and Genomics
- The demographics of the ubiquitin system
- (2015) Michael J. Clague et al. TRENDS IN CELL BIOLOGY
- Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective
- (2015) Alan Talevi Frontiers in Pharmacology
- Vorinostat-An overview
- (2015) AdityaKumar Bubna INDIAN JOURNAL OF DERMATOLOGY
- Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells
- (2014) Haiying Sun et al. ACS Chemical Biology
- Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription
- (2014) Pei-Suen Tsou et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- IRAK signalling in cancer
- (2014) G W Rhyasen et al. BRITISH JOURNAL OF CANCER
- Enhanced Protein Degradation by Branched Ubiquitin Chains
- (2014) Hermann-Josef Meyer et al. CELL
- Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
- (2014) Zebo Huang et al. Future Oncology
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Cellular Inhibitor of Apoptosis (cIAP)-Mediated Ubiquitination of Phosphofurin Acidic Cluster Sorting Protein 2 (PACS-2) Negatively Regulates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Cytotoxicity
- (2014) Maria Eugenia Guicciardi et al. PLoS One
- Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas
- (2014) Benedict Yan et al. PLoS One
- IκB kinase ɛ (IKKɛ): A therapeutic target in inflammation and cancer
- (2013) Kelly Verhelst et al. BIOCHEMICAL PHARMACOLOGY
- Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
- (2013) C. E. Chee et al. ONCOLOGIST
- Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
- (2012) Kylie M. Wagstaff et al. BIOCHEMICAL JOURNAL
- NF- B, the first quarter-century: remarkable progress and outstanding questions
- (2012) M. S. Hayden et al. GENES & DEVELOPMENT
- The noncanonical NF-κB pathway
- (2012) Shao-Cong Sun IMMUNOLOGICAL REVIEWS
- New Molecular Bridge between RelA/p65 and NF-κB Target Genes via Histone Acetyltransferase TIP60 Cofactor
- (2012) Jung-Woong Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Importazole, a Small Molecule Inhibitor of the Transport Receptor Importin-β
- (2011) Jonathan F. Soderholm et al. ACS Chemical Biology
- Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers
- (2011) Reza Ehsanian et al. Cell Communication and Signaling
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- A Cell-penetrating Peptide Suppresses Inflammation by Inhibiting NF-κB Signaling
- (2011) Yu Fu Wang et al. MOLECULAR THERAPY
- Inhibiting NF-κB activation by small molecules as a therapeutic strategy
- (2010) Subash C. Gupta et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Acetylation of p65 at lysine 314 is important for late NF-κB-dependent gene expression
- (2010) Karin M Rothgiesser et al. BMC GENOMICS
- Posttranslational modifications of NF-κB: Another layer of regulation for NF-κB signaling pathway
- (2010) Bo Huang et al. CELLULAR SIGNALLING
- Regulation and Function of NF-κB Transcription Factors in the Immune System
- (2009) Sivakumar Vallabhapurapu et al. Annual Review of Immunology
- IRAK-4 Inhibitors for Inflammation
- (2009) Zhulun Wang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- A Ubiquitin Replacement Strategy in Human Cells Reveals Distinct Mechanisms of IKK Activation by TNFα and IL-1β
- (2009) Ming Xu et al. MOLECULAR CELL
- Regulation of the RelA (p65) transactivation domain
- (2008) John M. O'shea et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Shared Principles in NF-κB Signaling
- (2008) Matthew S. Hayden et al. CELL
- Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes
- (2008) Allison B. Goldfine et al. CTS-Clinical and Translational Science
- The value of proteasome inhibition in cancer
- (2008) Boris Cvek et al. DRUG DISCOVERY TODAY
- Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation
- (2008) D. J. Mahoney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New insights into NF-κB regulation and function
- (2008) Shao-Cong Sun et al. TRENDS IN IMMUNOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started